SAN CARLOS, Calif., Aug. 19, 2015 /PRNewswire/ — Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced its pleasure to be a premier sponsor for the Discovery on Target Conference in Boston, MA on September 21-24th, 2015. The Quantitative Systems Pharmacology Tract at the conference is designed as a knowledge and opinion exchange forum, highlighting strategy and implementation of QSP from early discovery to early clinical development in the pharmaceutical industry. In addition to its sponsorship, Rosa will be presenting a talk and teaching a short course as part of the QSP program.
Photo – http://photos.prnewswire.com/prnh/20150818/259443LOGO
Dr. Ananth Kadambi, Senior Vice President, PhysioPD™, will present "Creating and Performing Research with PhysioPD™ Research Platforms: Overview and Case Study" on Wednesday, September 23rd at 4:35 PM. The talk will focus on the process of creating and conducting research using PhysioPD Platforms to drive scientific innovation in the pharmaceutical industry. PhysioPD Platforms are QSP models that are designed with multidisciplinary client team input. The PhysioPD research approach is designed to impact client decisions and has been successful for dozens of therapeutic indications.
Christina Friedrich Ph.D., Chief Engineer, will present the Short Course "Using Mechanistic Physiological Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) Approach" on Wednesday, September 23rd at 7:00 – 9:00 PM. The course will cover what mechanistic, physiological QSP models are, how they are built, and how they can be applied. The course introduces Rosa's Model Qualification Method (MQM), a systematic approach for ensuring a model is fit for the purpose it is intended, and illustrates concepts with examples and case studies.
"Rosa & Co. is honored to be a premier sponsor for the QSP tract and to share our perspective, gained from a more than a decade of experience on the forefront of commercial QSP applications and observing its impact on the pharmaceutical industry."
– Dr. Ron Beaver, Founder & CEO, Rosa & Co.
About Rosa
Rosa helps clients with their critical decisions – from preclinical through clinical development – with creation and use of mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Addressing the full spectrum of R&D related challenges from targets to outcomes, Rosa offers customized innovative PhysioPD™ Research Platforms. Rosa's clients participate in Platform creation, testing, and biological simulation research. Clients retain the Platforms to perform research to inform decisions and better understand implications for their drug development programs. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has completed hundreds of engagements with clients in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com/news.html
Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.
Media Contact:
Stephanie Sherman
Email
425-591-5738